EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Fulgent Genetics Inc (FLGT) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of Fulgent Genetics Inc $16.32, price $21.65, upside -24.6%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US3596641098

FG Fulgent Genetics Inc logo Thin data Sep 23, 2026

Fulgent Genetics Inc

FLGT · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $16.32 · Overvalued (−25%)
!Quality 49/100
!Weak Growth (revenue 5y −5.2 %/yr)
!Loss-making · -26.1% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers (5/11)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 1 out of 100
!Weak on future: 22 out of 100
Watch Fulgent Genetics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$110.87 $13.79 Fair Value $16.32 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $13.79 – $110.87 · fair‑value band $10.77 – $20.40 · the $21.65 price screens above the $16.32 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Fulgent Genetics in your weekly email

Every Wednesday you see whether Fulgent Genetics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.

Show more

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

Stock analysis

Fulgent Genetics Inc (FLGT) currently trades at $21.65, while our model-based Fair Value estimate is $16.32, implying the stock looks roughly 32.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: $10.77 (bear) to $20.40 (bull), the price of $21.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Fulgent Genetics Inc reported revenue of $323M in FY2025 versus $993M in FY2021, a compound −24.5%/yr. Reported net income was −$60.5M in FY2025.

Key figures

Market cap $666M · P/S ratio 1.63 · EPS (TTM) $−2.83 · Net margin −18.8% · Return on equity −8.1% · Return on assets (EBIT) −1.7% · Operating margin −39.4% · Revenue (TTM) $324M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 30% below its 52-week high and 61% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −25%, FLGT screens richer than that median.

Fair Value models

Bear $10.77 Fair Value $16.32 Bull $20.40
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $20.21 $27.08 $40.41 54
All 1 models by family
Asset-Based
NCAV (Graham) $20.21 $27.08 $40.41 54

Open the full fair value analysis →

Notify me when FLGT reaches fair value

Put FLGT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 49 · Market factors (momentum, volatility) 46

Profitability 6
Margins and returns on capital today
Quality Growth 49
Are margins and returns improving?
Cashflow 26
Earnings quality: real cash, not paper profit
Fin. Strength 78
Balance sheet, leverage, solvency risk
Investment 91
Disciplined investing over empire-building
Low Volatility 34
Calm price path (market factor)
Momentum 57
Price trend over the last 3–12 months (market factor)
52W Momentum 38
Distance to the 52-week high (market factor)
Net Issuance 74
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+13.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2020 (pandemic). Over 10 years: +42.2% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
68.8% (2020) → −28.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

FLGT screens 33% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Fulgent Genetics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 142 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside −25% · Above median
Profitability
Return on assets −6% · Bottom 25%
Net margin (TTM) −26% · Bottom 25%
Operating margin (TTM) −39% · Bottom 25%
Growth and dividend
Revenue growth 4% · Below median
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.60× · Cheapest 25%
P/S (TTM) 2.06× · Cheaper than median
PEG 1.32× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)1 · sector 0
FUTURE (revenue growth)22 · sector 24
PAST (return on equity)0 · sector 8
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 29

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $658.52 $682.58 +4%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$208.00 HK$228.80 +10%
Lonza Group LONN CHF 562.80 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $521.50 $495.84 −5%
Agilent Technologies, Inc A $167.26 $63.90 −62%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $247.46 $272.21 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Fulgent Genetics Inc · Fair Value
$16.32 −33%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Fulgent Genetics Inc Fair Value". https://www.fairvalue-calculator.com/stock/FLGT

Frequently asked questions

Is Fulgent Genetics Inc (FLGT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $16.32 versus a price of $21.65, about −25% upside (overvalued).
What is the fair value of FLGT?
Our model-based fair value for Fulgent Genetics Inc is $16.32 (as of Sep 23, 2026), built from audited fundamentals. The current price: $21.65.
What is the quality score of FLGT?
Fulgent Genetics Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fulgent Genetics Inc (FLGT)?
Our model-based price target is the fair value of $16.32 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $10.77, optimistic scenario $20.40. It is a calculation from audited fundamentals, not an analyst target.
What is the Fulgent Genetics Inc stock forecast for 2026?
Our models put fair value at $16.32, about −25% upside versus a price of $21.65 (overvalued). Cautious scenario $10.77, optimistic scenario $20.40. The calculation is refreshed regularly with new filings.
What is the revenue of Fulgent Genetics Inc (FLGT)?
Fulgent Genetics Inc reported trailing-twelve-month revenue of about $320M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Fulgent Genetics Inc (FLGT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fulgent Genetics Inc it is $16.32 per share (as of Sep 23, 2026), against a price of $21.65. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Fulgent Genetics Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, FLGT trades above its calculated fair value: price $21.65, fair value $16.32, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FLGT?
No. The price is what the market pays today ($21.65); the fair value is what the company's own numbers justify ($16.32). For Fulgent Genetics Inc the two are $5.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fulgent Genetics Inc worth?
The market values Fulgent Genetics Inc at about $666M (market capitalisation, as of Sep 23, 2026). Per share that is $21.65; our models calculate a fair value of $16.32 per share.
What do the bullish and bearish scenarios say about FLGT?
Our models span a range for Fulgent Genetics Inc: cautious scenario $10.77, base $16.32, optimistic $20.40 per share (as of Sep 23, 2026, price $21.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of FLGT?
The PEG ratio of Fulgent Genetics Inc is 1.32 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Fulgent Genetics Inc (FLGT)?
Balance-sheet figures for Fulgent Genetics Inc (as of Sep 23, 2026): return on equity −8.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is FLGT from its 52-week high?
Fulgent Genetics Inc trades at $21.65, about 30% below its 52-week high of $31.04 and 61% above the low of $13.46 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $16.32 is for.
Which stocks are comparable to Fulgent Genetics Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fulgent Genetics Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $21.65, calculated fair value $16.32 (−25%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FLGT calculated?
We run Fulgent Genetics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $16.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Fulgent Genetics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fulgent Genetics Inc (FLGT)?
The closing price on Sep 22, 2026 was $21.65. Our model-based fair value is $16.32, about −25% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fulgent Genetics Inc right now?
The price sits above even our optimistic bull case ($20.40). The favourable scenario is already priced in. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($10.77 to $20.40) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Fulgent Genetics Inc

How large is the market capitalisation of Fulgent Genetics Inc (FLGT)?
The market capitalisation of Fulgent Genetics Inc is $666M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fulgent Genetics Inc (FLGT)?
The price-to-sales ratio of Fulgent Genetics Inc is 1.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fulgent Genetics Inc (FLGT)?
Earnings per share at Fulgent Genetics Inc are $−2.83. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Fulgent Genetics Inc (FLGT)?
The net margin of Fulgent Genetics Inc is −18.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fulgent Genetics Inc (FLGT)?
The return on equity (ROE) of Fulgent Genetics Inc is −8.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fulgent Genetics Inc (FLGT)?
On an EBIT basis the return on assets of Fulgent Genetics Inc is −1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fulgent Genetics Inc (FLGT)?
The operating margin of Fulgent Genetics Inc is −39.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fulgent Genetics Inc (FLGT)?
Revenue at Fulgent Genetics Inc is growing +4.4% versus a year earlier (3y avg −19.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fulgent Genetics Inc (FLGT)?
Earnings per share at Fulgent Genetics Inc are growing −98.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Fulgent Genetics Inc (FLGT) generate?
The free cash flow of Fulgent Genetics Inc is −$124M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Fulgent Genetics Inc (FLGT) hold?
Fulgent Genetics Inc holds more cash than debt, $42.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Fulgent Genetics Inc in the live analysis

One click puts Fulgent Genetics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.